ERBB2 and breast cancer: Braso Maristany et al. observed no significant difference regarding subtypes identified by PAM50 distribution between HER2-0 and HER2-low in a cohort of 80 patients (p = 0.091) treated for BC (28.8% TNBC and 54.4% HR+) [36].